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ABSTRACT
Expressed polycistronic microRNA (miR) cassettes
have useful properties that can be utilized for
RNA interference (RNAi)-based gene silencing.
To advance their application we generated modular
trimeric anti-hepatitis B virus (HBV) Pol II cassettes
encoding primary (pri)-miR-31-derived shuttles that
target three different viral genome sites. A panel of
six expression cassettes, comprising each of the
possible ordering combinations of the pri-miR-31
shuttles, was initially tested. Effective silencing of
individual target sequences was achieved in trans-
fected cells and transcribed pri-miR trimers gener-
ated intended guide strands. There was, however,
variation in processing and silencing by each of
the shuttles. In some cases the monomers’ position
within the trimers influenced processing and this
correlated with target silencing. Compromised
efficacy could be compensated by substituting the
pri-miR-31 backbone with a pri-miR-30a scaffold.
Inhibition of HBV replication was achieved in vivo,
and in cell culture without disruption of endogenous
miR function or induction of the interferon response.
A mutant HBV target sequence, with changes in
one of the guide cognates, was also silenced by
the trimeric cassettes. The modular nature of the
cassettes together with compatibility with expres-
sion from Pol II promoters should be advantageous
for gene silencing applications requiring simultane-
ous targeting of different sites.
INTRODUCTION
The powerful and speciﬁc gene silencing that may be
achieved by harnessing the RNA interference (RNAi)
pathway is potentially useful for developing new thera-
pies required to treat a variety of diseases. In addition,
application of RNAi has utility for the study of gene
function. Both synthetic and expressed sequences are
being developed to activate RNAi (1). Exogenous
expression cassettes achieve this by transcribing mimics
of intermediates of the microRNA (miR) processing
pathway (2). Short hairpin RNAs (shRNAs), which
are typically expressed from Pol III promoters, simulate
precursor miR (pre-miR) products of Drosha/DGCR8
processing. Primary miR (pri-miR) shuttles are analo-
gues of nascent miR transcripts and their processing is
compatible with expression from Pol II transcription
regulatory elements (3–7). This important property pro-
vides the means of improving control of production of
RNAi activators and thereby limiting unwanted oﬀ
target eﬀects caused by saturating the endogenous miR
pathway (8). Pri-miR-like shuttles are also thought to
eﬀect superior silencing by simulating natural miR pro-
cessing more closely. Processing of pri-miR shuttles by
Drosha/DGCR8, which is bypassed by shRNAs, may
improve entry into the RNAi pathway (4). pri-miR-30
was initially the most widely utilized (9–11) backbone,
but other pri-miR shuttles such as miR-155 (6) miR-31
and miR-122 (3) have since been used successfully to
generate exogenous RNAi eﬀecters. The polycistronic
arrangement of some naturally occurring miR clusters
is an additional property that may be exploited to gen-
erate combinatorial multitargeting RNAi expression cas-
settes (4,6,7). This is particularly useful to improve
knockdown eﬃcacy and overcome attenuation of silenc-
ing caused by target site mutation such as often occurs
during chronic viral infection. Recently, the miR-106 (7)
and miR-17-92 (4) polycistronic clusters have been used
successfully to generate multiplexed anti-HIV-1 RNAi
activators. To improve use of expressed multimeric
RNAi eﬀecters, a system that allows convenient assem-
bly, modiﬁcation to improve silencing eﬃcacy and which
causes knockdown without disrupting the endogenous
miR pathways would be valuable. We demonstrate
these attributes in a panel of anti-hepatitis B virus
(HBV) Pol II trimeric pri-miR cassettes, which are
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and in vivo.
MATERIALS AND METHODS
miR expression plasmids
Anti-HBV pre-miR DNA shuttles were generated
by annealing partly complementary pre-miR-31/5, -31/8,
31/9 and pre-miR30a/8 forward (F) and reverse (R) oligo-
nucleotides, which was followed by primer extension to
generate completely double-stranded DNA. The oligonu-
cleotide sequences were pre-miR-31/5F: 50-GTA ACT
CGG AAC TGG AGA GGG GTG AAG CGA AGT
GCA CAC GGG TTG AAC TGG GAA CGA CG-30,
pre-miR-31/5R: 50-CTG CTG TCA GAC AGG AAA
GCC GTG AAT CGA TGT GCA CAC GTC GTT
CCC AGT TCA ACC CGT-30, pre-miR-31/8F: 50-GTA
ACT CGG AAC TGG AGA GGC AAG GTC GGT
CGT TGA CAT TGG TTG AAC TGG GAA CGA
AA-30, pre-miR-31/8R: 50-CTG CTG TCA GAC AGG
AAA GCT AAG GTT GGT TGT TGA CAT TTC
GTT CCC AGT TCA ACC AAT-30, pre-miR-31/9F:
50-GTA ACT CGG AAC TGG AGA GGA TTT ATG
CCT ACA GCC TCC TAG TTG AAC TGG GAA CGA
AG-30, pre-miR-31/9R: 50-CTG CTG TCA GAC AGG
AAA GCC TTT ATT CCT TCA GCC TCC TTC GTT
CCC AGT TCA ACT AGG-30, pre-miR-30a/8F: 50-TGC
TGT TGA CAG TGA GCG ACT CAA GGT CGG TCG
TTG ACA TTG CTG TGA AGC CAC AGA TGG GC-
30 and pre-miR-30a/8R: 50-GAA GTC CGA GGC AGT
AGG CAG CTC AAG GTC GGT TTG ACA TTG CCC
ATC TGT GGC TTC ACA G-30. Extended pre-miR
DNA was used as template to generate the pri-miR shuttle
sequences using PCR with pri-miR-31F: 50-GCT AGC
CAT AAC AAC GAA GAG GGA TGG TAT TGC
TCC TGT AAC TCG GAA CTG GAG AGG-30, pri-
miR-31R: 50-AAA AAA ACT AGT AAG ACA AGG
AGG AAC AGG ACG GAG GTA GCC AAG CTG
CTG TCA GAC AGG AAG C-30, pri-miR-30a F:
50-GAT CGC TAG CTT AAC CCA ACA GAA GGC
TAA AGA AGG TAT ATT GCT GTT GAC AGT GAG
CGA C-30 and pri-miR-30a R: 50-GAT CAC TAG TAA
AAA ACA AGA TAA TTG CTC CTA AAG TAG CCC
CTT GAA GTC CGA GGC AGT AGG CA-30 primers.
The pri-miR-31 and pri-miR-30a sequences were then
inserted into the PCR cloning vector, pTZ57R/T
(InsTAclone
TM PCR cloning Kit, Fermentas, MD,
USA) to generate pTZ pri-miR-31/5, pTZ pri-miR-31/8,
pTZ pri-miR-30a/8 and pTZ pri-miR-31/9. Propagation
of pTZ pri-miR-122/5 has been described previously (3).
To produce U6-driven pri-miR expression plasmids (pTZ
U6-pri-miR-31/5, pTZ U6-pri-miR-31/8 and pTZ U6-pri-
miR-31/9), the pri-miR-31 shuttle sequences were excised
with NheI and ScaI then inserted into equivalent sites
downstream of the U6 promoter in the pTZ-U6 vector
(12). Pol II-driven miR expression plasmids (pCI-pri-
miR-31/5, 31/8 and 31/9) were constructed by excising
the pri-miR-31 shuttle sequences with SalI and XbaI and
ligating these fragments to XhoI and XbaI sites of pCI-
neo (Promega, WI, USA).
Trimeric shuttle cassettes, containing pri-miR-31, pri-
miR-30a and pri-miR-122 sequences, were formed by
inserting combinations of pri-miR-31/5, pri-miR-31/8,
pri-miR-30a/8, pri-miR-31/9 and pri-miR-122/5 sequences
downstream of the CMV immediate early promoter
enhancer. A total of eight trimeric cassettes was generated
(pri-miR-31/5-8-9, pri-miR-31/5-9-8, pri-miR-31/8-5-9,
pri-miR-31/8-9-5, pri-miR-31/9-5-8, pri-miR-31/9-8-5,
pri-miR-31/5-31/9-30a/8 and pri-miR-122/5-31/9-30a/8).
Six of the trimeric cassettes comprised pri-miR-31-derived
sequences exclusively, while pri-miR-31/5-31/9-30a/8, and
pri-miR-122/5-31/9-30a/8 also included pri-miR-30a and
pri-miR-122 scaﬀolds. Similar cloning strategies were used
to propagate each of the trimers. As an example, to gen-
erate the pri-miR-31/5-8-9 cassette, pri-miR-31/8 was
excised from pTZ pri-miR-31/8 with NheI and EcoRI
and ligated to pTZ pri-miR-31/5 that had been digested
with SpeI and EcoRI to create pTZ pri-miR-31/5-8.
Similarly, the sequence encoding pri-miR-31/9 was then
excised from pTZ pri-miR-31/9 with NheI and EcoRI
and ligated to SpeI and EcoRI sites of pTZ pri-miR-31/
5-8. Successful ligation resulted in formation of pTZ pri-
miR-31/5-8-9. The trimer cassettes were excised with NheI
and XbaI and inserted at equivalent sites of pCI-neo
to generate the CMV panel of multimeric cassettes.
Sequences were veriﬁed using standard automated
dideoxy chain termination reactions.
miR target plasmids
To produce dual luciferase reporter plasmids containing
sites individually targeted by pri-miR-31/5, pri-miR-31/8,
pri-miR-31/9, pri-miR-30a/8 and pri-miR-122/5 primers
were designed to amplify HBV coordinates 1575–1599
(5T), 1678–1702 (8T) and 1774–1798 (9T) (Genbank
accession J02203). Oligonucleotide sequences, which also
introduced a SpeI site at the 30 end of the amplicons, were
5T F: 50-CCG TGT GCA CTT CGC TTC AC-30,5 TR :
50-ACT AGT CAG AGG TGA AGC GA-30,8 TF :
50-CAA TGT CAA CGA CCG ACC TT-30, 8T: R
50-ACT AGT GCC TCA AGG TCG GT-30,9 TF :
50-TAG GAG GCT GTA GGC ATA AA-30 and 9T R:
50-ACT AGT ACC AAT TTA TGC CT-30. Puriﬁed frag-
ments were incorporated into the pTZ57R/T PCR cloning
vector (InsTAclone
TM PCR cloning Kit, Fermentas, MD,
USA) and the insert was removed with SalI and SpeI then
ligated to the XhoI and SpeI sites of psiCHECK2.2 (3)
that had been previously modiﬁed from psiCHECK
TM-2
(Promega, WI, USA), to generate psiCHECK-5T,
psiCHECK-8T and psiCHECK-9T with the target sites
downstream of the Renilla luciferase reporter open read-
ing frame (ORF). The reporter target vector psiCHECK-
HBx, which contains an intact HBx target sequence down-
stream of the Renilla ORF within psiCHECK
TM-2
(Promega, WI, USA), has been described previously
(13). The derivative with mutant HBx target,
psiCHECK-mHBx, was propagated using PCR. Brieﬂy
mHBx was ampliﬁed from psiCHECK-HBx using
mHBx F (50 GAT CCG GTC CGT CTG CAG TTC
GGT TGT CCT CTG CAC GTT GCA TGG AG 30)
and mHBx R (50 GAT CGC GGC CGC CCG GGT
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sequence (underlined) were incorporated within the for-
ward PCR primer. The resultant amplicon included
RsrII and NotI sites at the 50 and 30 ends, respectively.
After insertion into the pTZ57R/T PCR cloning vector
(InsTAclone
TM PCR cloning Kit, Fermentas, MD,
USA) and sequence veriﬁcation, mHBx was excised with
RsrII and NotI then used to replace HBx in psiCHECK-
HBx and generate psiCHECK-mHBx. Presence of a PstI
restriction digestion site (bold font in mHBx F primer),
which is absent from wild-type HBx, was used to verify
insertion of the intended mutant sequences. The HBV
target plasmids, pCH-9/3091 (14) and pCH-FLuc (3),
have been described previously.
miR-16 sponge and dual luciferase target
The U6-driven miR-16 sponge (15) was generated by clon-
ing seven copies of an imperfectly complementary target
of miR-16 into the U6+27 sequence (16–18). A single
copy of duplex DNA, comprising annealed oligonucleo-
tides encoding a single copy of the miR-16 target site
(miR-16S) with single nucleotide 30 A overhangs, was ini-
tially ligated to pTZ57R/T to create pTZ-miR-16S 1.
The resulting target sequence included an XhoI site that
was 50 of the target and SalI and NotI sites 30 of this
sequence. Oligonucleotide sequences used to generate the
inserts were miR-16S F: 50-CTC GAG CGC CAA TAT
TAT GTG CTG CTA GTC GAC GCG GCC GCA-30
and miR-16S R: 50-GCG GCC GCG TCG ACT AGC
AGC ACA TAA TAT TGG CGC TCG AGA-30. The
miR-16S 1 sequence was restricted from pTZ-miR-
16S 1R (insert in reverse orientation with respect to the
 -galactosidase gene) with ApaI and PvuII and cloned into
the ApaI and HincII sites of pGEM-T Easy (Promega,
WI, USA) to create pG-miR-16S 1. To generate vectors
with tandem copies of the miR-16S sequence, pG-miR-
16S 1 was digested with XhoI and ScaI and separately
with SalI and ScaI. The fragments containing the miR-16S
sequence from each digestion were ligated to create pG-
miR-16S 2. pG-miR-16S 3 and pG-miR-16S 4 were
generated using similar procedures. Finally, the vectors
containing three and four tandem copies of the miR-16S
sequence were used to create pG-miR-16S 7.
The U6+27 sequence (18) was produced using a two-
step PCR of the human U6 promoter. U6 forward (U6F,
50-GAT CTC TAG AAA GGT CGG GCA GGA AGA
GGG-30) and U6+27 reverse 1 (U6+27 R1, 50-CTC
GAG TAG TAT ATG TGC TGC CGA AGC GAG
CAC GGT GTT TCG TCC TTT CCA C-30) primers
used in the ﬁrst round of ampliﬁcation. Amplicons from
this reaction were used as template for the second round
of PCR using the U6+27 R2 primer (50-GAT CAA AAA
AGC GGA CCG AAG TCC GCT CTA GAC TCG AGT
AGT ATA TGT GCT G-30) and U6F primer. The com-
plete U6+27 sequence was inserted into the PCR cloning
vector pTZ57R/T to generate pTZ-U6+27. The miR-
16S 7 sequence was removed from pG-miR-16S 7 with
XhoI and SalI and ligated to the XhoI site of pTZ-
U6+27 to produce the pTZ-U6-miR-16S 7 sponge plas-
mid. To generate the psiCHECK-miR-16T 7 target
vector containing 7 miR-16 sites downstream of the
Renilla luciferase ORF, the miR-16S 7 sequence was
restricted from pG-miR-16S 7 with XhoI and NotI and
inserted into equivalent sites of psiCHECK
TM-2
(Promega, WI, USA).
Cell culture, transfection, northern blot analysis and dual
luciferase assay
Huh7 cells were cultured in DMEM (Lonza, Basel,
Switzerland) supplemented with 10% fetal calf serum
(Gibco BRL, UK). To determine the eﬃcacy of individual
pri-miR monomers in the context of multimeric cassettes,
each trimeric plasmid (800ng) was co-transfected
with psiCHECK-5T, psiCHECK-8T or psiCHECK-9T
(80ng). Luciferase activity was assayed using the Dual-
Luciferase Reporter Assay System (Promega, WI,
USA) and Renilla luciferase to Fireﬂy luciferase activity
was determined. Silencing of mutant HBx sequences was
assayed similarly by using psiCHECK-HBx and
psiCHECK-mHBx dual luciferase reporter vectors. To
assess HBV knockdown eﬃcacy of the Pol III and Pol II
pri-miR shuttles, Lipofectamine 2000
TM (Invitrogen, CA,
USA) was used to co-transfect 80ng pCH-FLuc, 800ng of
the relevant pri-miR shuttle plasmid, together with eﬀecter
plasmid or vector control plasmid according to previously
described methods (3). phRL-CMV (Promega, WI, USA),
a plasmid constitutively expressing Renilla luciferase, was
included in all transfections. Forty-eight hours after trans-
fection cells were assayed for luciferase activity using the
Dual-Luciferase Reporter Assay System (Promega, WI,
USA) and the ratio of Fireﬂy luciferase to Renilla lucifer-
ase activity was calculated.
Northern blot analysis was performed on RNA
extracted from cells transfected with the various miR-31
shuttle constructs according to previously described meth-
ods (3). The probes for the 5, 8 and 9 guide sequences were
50-CCG TGT GCA CTT CGC TTC-30,5 0-CAA TGT
CAA CGA CCG ACC-30 and 50-TAG GAG GCT GTA
GGC ATA-30, respectively. Scanned autoradiographs
were used to quantitate guide bands using KODAK
MI Software.
Knockdown of HBV replication was assessed in cells
co-transfected with pCH-9-3091(14) and relevant RNAi
eﬀecter plasmid. Forty-eight hours after transfection
growth medium was harvested and HBsAg secretion mea-
sured by ELISA using the MONOLISA HBs Ag
ULTRA kit (Bio-Rad, CA, USA).
Activation of the interferon (IFN) response was
assessed using previously described methods (19). Assays
to assess saturation of the endogenous miR pathway were
performed in Huh7 cells cotransfected with 80ng
psiCHECK-miR-16T 7 and 800ng RNAi eﬀecter plas-
mids or miR-16 sponge plasmid. Luciferase assays were
performed as described above.
Assessment of efficacy of pri-miR-31 shuttles in vivo
Mice were injected using the hydrodynamic injection
procedure with a combination of 5mg pCH-9-3091 (14),
5mg of RNAi expression vector, 5mg of control U6 (pTZ-
U6 vector (12)) or CMV (pCI-neo, Promega, WI, USA)
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psiCHECK2.2. Blood was collected 3 and 5 days post-
injection. Experiments were carried out according to pro-
tocols approved by the University of the Witwatersrand
Animal Ethics Screening Committee. ELISA for HBsAg
levels was performed on serum samples using the
MONOLISA HBs Ag ULTRA kit from Bio-Rad.
Statistical analysis
Data are expressed as the mean   standard error of the
mean (SEM). Statistical diﬀerence was considered signiﬁ-
cant when P<0.05 and was determined according to the
Student’s paired two-tailed t-test. Calculations were done
with the GraphPad Prism software package (GraphPad
Software Inc., CA, USA).
RESULTS
Design of trimeric pri-miR expression cassettes
Structure of the expression cassettes producing trimeric
anti-HBV pri-miR-31 mimics is depicted schematically in
Figure 1A. The pri-miR-31 backbone was initially selected
as we have previously shown that single unit shuttles
with this scaﬀold can be used to generate eﬃcient Pol II
anti-HBV expression cassettes (3). Sequences encoding the
pri-miR-31 trimers were located within an exon and down-
stream of a CMV Pol II transcription controlling element
and intron sequence. Trimeric cassettes were designed
such that pre-miRs comprised 59nt and were ﬂanked by
51nt of natural pri-miR-31/derived sequences (Figure 1B).
According to this scheme, the mature anti-HBV miRs
were predicted, using the MFold algorithm (20), to
have a similar structure to that of naturally occurring
pri-miR-31. To assess the modular nature of the
cassettes, six diﬀerent trimeric expression cassettes were
generated using all possible ordering combinations of
the three pri-miR-31 shuttles. Computer-based predictions
indicated that the intended miR-31-like structures of the
trimeric cassettes were energetically most favourable
and similar for each of the six ordering combinations.
The calculated G values of each was approximately
–195kcal/mol.
Detection of processed pri-miR sequences and silencing
of individual targets
To verify formation of individual guide sequences, north-
ern blot analysis was carried out on RNA extracted from
Huh7 liver-derived cells transfected with DNA-expressing
pri-miR-31 shuttles (Figure 2A–C). Hybridization to a
probe complementary to the intended miR-31/5 HBV
guide showed heterogenous processing to form guide
sequences of 20–22nt in length. Guide strand 5 produc-
tion was similar when generated from monomeric and
trimeric cassettes and was not aﬀected by shuttle position
within the anti-HBV polycistron. As expected, measure-
ment of relative guide band intensities showed that the
20–22nt HBV anti-sense sequence was present in consid-
erably higher amounts in cells transfected with U6 shRNA
5-expressing plasmid when compared to cells transfected
with the pri-miR trimer shuttles. Speciﬁc knockdown of
target 5 sequence, assessed using a dual luciferase reporter
system, was similar and highly eﬀective ( 90%) for the
U6 shRNA 5 and each of pri-miR-31 shuttle expression
cassettes (Figure 2D). Northern blot analysis to detect
guide 8 revealed a single band of 21nt (Figure 2B),
which was distinct from the heterogenous mature
pri-miR-31/5 sequences. Interestingly, no mature pri-
miR-31/8 was detectable in RNA extracted from cells
transfected with CMV pri-miR-31/9-8-5 and CMV pri-
miR-31/5-9-8. This suggests that pri-miR-31/8 shuttle
position within the trimer aﬀects processing, and presence
of pri-miR-31/9 immediately upstream of pri-miR-31/8
may be responsible for compromised guide 8 production.
Assay of knockdown using a dual luciferase assay with
miR-31/8 target alone, conﬁrmed that knockdown of
reporter expression correlated with detection of mature
miR sequences (Figure 2E). Interestingly, guide produced
from the U6 shRNA 8 cassette was slightly larger than
that of the CMV miR-31-derived sequences. It is likely
that the diﬀerences in secondary structure of the shRNA
8 and pri-miR-31/8 RNA, as well as the involvement of
Drosha in miR shuttle processing, are responsible for gen-
eration of guide strands of diﬀerent molecular weight.
Analysis of silencing and processing of pri-miR-31/9
sequences showed less eﬃcient knockdown (45–80%)
of ORF containing pri-miR-31/9 target (Figure 2F),
which correlated with lower eﬃciency of pri-miR-31/9
guide production (Figure 2C). Although there is varia-
tion in the eﬃciency of individual guide strand production
and knockdown, these data indicate that the pri-miR-31
scaﬀold is useful for production of Pol II trimeric
cassettes.
Figure 1. Trimeric pri-miR-31 expression cassettes. (A) Schematic illus-
tration of pri-miR-31 shuttle expression cassettes showing upstream
CMV promoter, intron and three miR mimic sequences with down-
stream transcription termination signal [poly(A)]. Pre-miR shuttles
were inserted in an exon and were ﬂanked by 51nt of pri-miR-31-
derived sequences. (B) Pri-miR-31/5, pri-miR-31/8 and pri-miR-31/9
anti-HBV sequences. Predicted structures and sequences of anti-HBV
pri-miR-31 derivatives. The sequences of the putative pre-miRs gener-
ated after Drosha/DGCR8 processing are indicated in colour (purple
and red) and the mature processed guide sequences that are selected
after Dicer processing and strand selection by RISC are indicated in
red only.
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Sequence-speciﬁc properties of the individual anti-HBV
pri-miR-31 shuttles as well as position of monomer shut-
tles within the trimers are likely to inﬂuence their proces-
sing and silencing eﬃciency. To assess the eﬀect of
pri-miR backbone scaﬀold sequences within the expres-
sion cassettes, silencing of target 8 sequences by an
expanded panel of trimeric expression cassettes that
included pri-miR-122/5 and pri-miR-30a/8 shuttles was
measured (Figure 3). Each of the six pri-miR-31 trimers
together with pCMV pri-miR-31/5-31/9-30a/8 and pCMV
pri-miR-122/5-31/9-30a/8 were co-transfected with
psiCHECK 8T. As described before (Figure 2E), knock-
down of Renilla luciferase activity was poor with cassettes
containing pri-miR-31/5-9-8 and pri-miR-31/9-8-5.
However, eﬃcient inhibition of reporter gene activity
was achieved with pCMV pri-miR-31/5-31/9-30a/8 and
pCMV pri-miR-122/5-31/9-30a/8 (Figure 3B). This indi-
cates that substitution of the pri-miR-31 scaﬀold with a
pri-miR-30a backbone restores target 8 silencing. In addi-
tion, inclusion of the pri-miR-122/5 monomer, which we
have previously shown to act eﬃciently against HBV (3),
does not compromise silencing by the pri-miR-30a/8
monomer. Thus, in addition to allowing improved silenc-
ing eﬃciency by changing monomer positions within
the trimers, the cassettes described here have the added
advantage of permitting the changing of pri-miR shuttle
backbones to compensate for any compromised silencing
eﬃcacy of pri-miR-31 scaﬀolds.
miR-mediated inhibition of markers of HBV replication
in transfected cells and in vivo
Target sites of the individual miR cassettes are located
within the HBV X (HBx) ORF (Figure 4A). This sequence
is conserved, common to all viral transcripts and has been
shown to be a good target for RNAi-based HBV silencing
(19). A dual luciferase assay, in which the surface ORF of
pCH-9/3091 was substituted with a Fireﬂy luciferase ORF,
demonstrated that each of the trimeric cassettes achieved
good knockdown when all three cognates of the intended
miR-31/5, miR-31/8 and miR-31/9 guides were present
(Figure 4B). As an initial assessment of pri-miR-31
trimer-mediated inhibition of HBV replication, Huh7
liver-derived cells were transfected with the pCH-9-3091
HBV replication competent plasmid (14), together with
the panel of RNAi expression plasmids. Secreted HBV
surface antigen (HBsAg), which is a reliable indicator of
HBV replication in our hands (3,19,21), was determined
thereafter in the culture medium (Figure 4C). Knockdown
of  90% was achieved. This correlated with the inhibitory
eﬀect that was observed when using the dual luciferase
reporter system to measure silencing of individual targets
(Figure 2D–F) and also inhibition of a Fireﬂy luciferase-
HBx reporter gene construct (Figure 4B). To determine
silencing of target genes in vivo in a model that simulates
Figure 2. Processing and knockdown eﬃcacy of trimer shuttles. Northern blot analysis of RNA extracted from cells that had been transfected with
indicated expression cassettes. Hybridization was carried out with probes complementary to putative guide 5 (A), guide 8 (B) or guide 9 (C). Bands
corresponding to guide sequence (G) and precursors (P) are indicated by the arrow and square bracket respectively. Re-hybridization of blots to
U6 snRNA was carried out to conﬁrm equal RNA loading in each of the lanes (lower panels). Oligodoexynucleotide length (nt) of labelled
single-stranded DNA markers is indicated on the left of each panel. Approximate band intensities of miR-derived guides relative to the
U6 shRNA guides (%) are indicated below. Assessment of knockdown eﬃcacy of trimer shuttles using a dual luciferase reporter gene assay in
which a target sequence complementary to guide 5 (D), 8 (E)o r9( F) only was inserted downstream of the Renilla luciferase reporter ORF of
psiCHECK 2.2. Data are represented as mean ratios of Renilla to Fireﬂy luciferase activity ( SEM) and are normalized relative to the cells treated
with backbone plasmid lacking RNAi eﬀecter sequences (mock).
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lication competent plasmid together with a selection of
vectors encoding pri-miR-31 shuttles using the hydrody-
namic procedure (22). Signiﬁcant knockdown of HBsAg
was observed at Days 3 and 5 after the injection, and the
eﬀects appeared to be independent of promoter interfer-
ence (Figure 4D). These ﬁndings conﬁrm that trimeric pri-
miR-31 shuttles are capable of silencing HBV replication
and verify that they are active against transcripts that are
produced during viral replication in vivo.
A potential advantage of employing multimeric cas-
settes to inhibit viral replication is that viral escape result-
ing from emergence of evading mutations is limited. A
dual luciferase assay was undertaken to assess whether
HBV target silencing occurred when mutations were intro-
duced into the target 5 site of HBV (Figure 5A). Co-trans-
fection of cells was carried out with each plasmid encoding
the panel of eight trimeric expression cassettes together
with wild-type or mutant HBx target. Silencing of reporter
gene expression was achieved with all trimeric expression
cassettes with the exception of mutant target silencing
by CMV pri-miR-31/5-9-8 and CMV pri-miR-31/9-8-5.
This was expected as these two expression cassettes are
known to generate antiHBV guide 9 in low amounts and
be defective with respect to guide 8 production (Figure 2).
Importantly, mutant target silencing was restored in these
cassettes by changing the pri-miR-31/8 monomer for a
pri-miR-30a/8 unit, and conﬁrms earlier observations
(Figure 3) that target 8 silencing may be improved by
substituting the pri-miR scaﬀold of its guide. Thus tri-
meric pri-miR cassettes are capable of eﬃciently silencing
targets containing one mutant guide cognate and defective
silencing may be overcome by changing the order of the
miR units or scaﬀold sequence within the monomers.
Exclusion of non-specific effects induced by pri-miR-31
trimer cassettes
Veriﬁcation that the pri-miR-31 trimer cassettes are
indeed non-toxic and induce gene silencing by an RNAi-
mediated mechanism is important to establish. To address
this, disruption of the endogenous miR pathway and stim-
ulation of the innate IFN response by pri-miR-31 trimer
cassettes were assessed. Measurement of IFN-  mRNA
concentration in cells transfected with trimer expression
cassettes showed no elevation of this transcript, indicating
that little or no immunostimulation is caused by IFN
pathway induction (Figure 6). To assess disruption of
the endogenous miR pathway, we adapted the recently
described method that utilizes miR sponges as a con-
trol to verify derepressive eﬀects of endogenous miR
Figure 3. Use of shuttles containing pri-miR-31, pri-miR-30a and pri-miR-122 to improve silencing of HBV target 8 sequence. (A) Predicted
structures and sequences of pri-miR-30a/8 and pri-miR-122/5 anti-HBV sequences. Colour coding of the sequences representing putative pre-
miRs and mature guides are as indicated in Figure 1B. (B) Assessment of knockdown eﬃcacy of trimer shuttles using a dual luciferase reporter
gene assay in which a target sequence complementary to guide 8 was inserted downstream of the Renilla luciferase reporter ORF of psiCHECK2.2.
Data are represented as mean ratios of Renilla to Fireﬂy luciferase activity ( SEM) and are normalized relative to the mock-treated cells.
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erated in which seven copies of an imperfectly matched
endogenous miR-16 target were inserted downstream of
the Renilla luciferase ORF (Figure 7A). Perturbations in
miR-16 translational suppression could be detected sensi-
tively by measuring Renilla/Fireﬂy luciferase reporter
gene activity. miR-16 was selected for this assay as it is
expressed in a variety of tissues (23) and can be conveni-
ently used to determine disruption of natural miR func-
tion. A miR sponge expression cassette that encodes seven
tandemly repeated miR-16 target sites was used to control
for endogenous miR derepression (Figure 7B). Analysis
revealed that co-expression of each of the trimeric con-
structs within transfected cells did not cause derepression
of miR-16 inhibition of its cognate in the reporter fusion
sequence (Figure 7C). The Pol II promoter-controlled
expression of trimeric anti-HBV miR-31 shuttles,
therefore, cause no detectable toxicity that results from
IFN response induction or disruption of the endogenous
miR pathway.
DISCUSSION
The powerful gene silencing that can be achieved by
harnessing RNAi has facilitated development of new
approaches to inhibition of pathology-causing genes and
the study of gene function (1). Although synthetic siRNAs
have been favoured as RNAi activators for many such
applications, use of expressed silencing sequences has sev-
eral advantages. These include achievement of sustained
knockdown, compatibility with recombinant viral vectors
and evasion of some of the immunostimulatory properties
of exogenous synthetic sequences (24). Convenient expres-
sion of silencing sequences that eﬃciently target multiple
Figure 4. Trimer expression cassette-mediated knockdown of HBV replication in cultured cells and in vivo.( A) Organization of the HBV genome
with ORFs and sites within the pCH-9/3091 vector that are targets complementary to processed products of pri-miR-31/5, pri-miR-31/8 and pri-miR-
31/9 expressing vectors. Four parallel arrows indicate the HBV transcripts, which have common 30 ends, and include the pri-miR-31/5, pri-miR-31/8
and pri-miR-31/9 targets. The pCH-9/3091-derived pCH-FLuc target vector has the Fireﬂy luciferase ORF substituted for the preS2/S HBV
sequence. (B) Luciferase reporter gene-based assay of knockdown eﬃcacy in situ. pCH-FLuc was cotransfected with plasmids containing indicated
RNAi expression cassettes in addition to a plasmid constitutively expressing Renilla luciferase. Results are given as ratios of Fireﬂy to Renilla
luciferase activity. Column-labelled negative represents data from transfections that excluded the pCH-FLuc plasmid. (C) Concentration of HBsAg in
culture supernatants of Huh7 cells 48h after transfection with pCH-9/3091 HBV replication-competent plasmid together with indicated anti-HBV
expression cassettes. Column-labelled negative represents data from transfections that excluded the pCH-9/3091 HBV plasmid. (D) Silencing of HBV
replication in vivo. Serum concentration of HBsAg was measured at Days 3 and 5 after hydrodynamic injection of mice with replication-competent
vector and plasmids expressing anti-HBV RNAi sequences. Mock injections included control backbone plasmids containing U6 or CMV promoters
that did not express anti-HBV RNAi eﬀecters.
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knockdown and counter evading target mutations.
Achieving this without causing unintended oﬀ target
eﬀects and needing to utilize complex systems that require
multiple expression cassettes is desirable. The engineered
polycistrons described here provide a suitable method to
attain these objectives. Cassettes were generated using pri-
miR-31-, pri-miR-30a- and pri-miR-122-derived modules,
which were combined as trimers and expressed from a Pol
II promoter. Eﬃcient processing of the shuttles and silenc-
ing of HBV cognates was observed without evidence
for disruption of the endogenous miR pathway.
Detailed analysis revealed variation in eﬃcacy of indi-
vidual units that was dependent on speciﬁc sequences of
the monomers as well as their position within the engi-
neered polycistrons. Despite simultaneous production of
three RNAi eﬀecters from a single transcript, the mature
guide sequences were not formed in equimolar amounts.
Although knockdown of single targets may be compro-
mised as a result of poor processing of individual guides,
the modular nature of the cassettes facilitates improve-
ment of defective silencing. Rearranging the order of the
pri-miR units, which is not easily achieved with polycis-
tronic miR cluster mimics, may restore function of indi-
vidual miR shuttles. In addition, the cassettes described
here allow improvement of eﬃcacy to be achieved by
Figure 5. Dual luciferase reporter assay to detect silencing of wild-type HBx and mutant HBx target sequences using pri-miR expression cassettes.
(A) The dual luciferase reporter vectors include the entire wild-type or mutant HBx target sequence downstream of the Renilla luciferase ORF.
Guide 5 sequence is indicated in red, and mutations within its mutant HBx cognate are indicated in blue. (B) Assessment of knockdown eﬃcacy of
trimer shuttles using the psiCHECK-based dual luciferase reporter gene assay in which wild-type HBx or mutant HBx had been inserted downstream
of the Renilla ORF. Data are represented as mean ratios of Renilla to Fireﬂy luciferase activity ( SEM) and are normalized relative to the mock-
treated cells.
Figure 6. Assessment of IFN response induction by miR-expression
cassettes. IFN-  mRNA concentrations were determined in HEK293
cells, which were transfected with the indicated miR-encoding cassettes,
or with poly(I–C) as positive control. RNA was extracted from the cells
24h later and then subjected to quantitative RT-PCR to determine
concentrations of IFN-  and GAPDH mRNA. Means ( SEM) of the
normalized ratios of IFN-  to GAPDH mRNA concentrations are
indicated from three independent experiments.
e91 Nucleic Acids Research,2009, Vol. 37,No. 13 PAGE8 OF10substituting poorly acting pri-miR-31 scaﬀolds with
other backbone shuttles, such as those derived from
pri-miR-30a and pri-miR-122. The sequence-speciﬁc dif-
ferences in individual guide processing and target knock-
down that we observed are not surprising but currently
diﬃcult to explain. Although computer-predicted struc-
tures of the shuttles were similar, empirical characteriza-
tion of the processing of expressed RNAi eﬀecters remains
critically important.
Previous investigations have demonstrated that a com-
binatorial approach to knockdown of HIV-1 replication
augments silencing and prevents the emergence of viral
escape mutants (25). It has been calculated that four
optimally acting individual antiviral guide sequences are
required to prevent HIV-1 escape from RNAi (26), and
anti-HIV-1 RNAi activators have been designed accord-
ingly (4,7). Unlike with HIV-1, the HBV genome com-
prises overlapping ORFs with embedded viral cis
elements (27). This highly compact arrangement of the
genome restricts ability of HBV to mutate without com-
promising its replication ﬁtness. The number of RNAi
eﬀecters within a combinatorial cassette that is required
to prevent emergence of HBV escape mutants is not estab-
lished, but it is likely to be fewer than the four that
are required for HIV-1. Nevertheless, although only
three pri-miR-31 shuttles were tested in the polycistronic
cassettes described here, it is likely that a larger number of
monomeric modules can be accommodated.
An important concern for the development of
RNAi-based therapy is avoidance of oﬀ target eﬀects.
Unintended consequences may result from disruption
of endogenous miR functions and silencing of normal cel-
lular genes that have partial sequence complementarity
to exogenous RNAi activators. We have shown that endo-
genous miR-16-mediated repression of a target reporter
fusion is unaﬀected by expression of the Pol II pri-miR-
31 trimer cassettes. Generating multiple silencing
sequences from an engineered polycistronic cassette poten-
tially increases the likelihood of causing unintended oﬀ
target eﬀects. Interaction of a guide seed region, compris-
ing nucleotides 2–8 from the 50 end, is potentially suﬃcient
to eﬀect translational suppression of a cellular target.
This weak sequence restraint emphasizes the importance
of utilizing potent expressed silencing sequences that
are eﬀective at low concentration, and also restricting
the expression of RNAi eﬀecters to target tissues.
Compatibility of polycistronic pri-miR shuttles with
expression from Pol II promoters, and eﬃcacy that is
equivalent to that of shRNA transcribed from a U6 pro-
moter, are useful features that may be harnessed to dimin-
ish unintended eﬀects. Compared to Pol III promoters,
Pol II transcription regulatory elements have greater
versatility that facilitates production of mature RNAi
eﬀecters without perturbing endogenous miR function.
In the case of developing RNAi-based HBV therapy,
expression cassettes containing liver-speciﬁc promoters
that are induced by target-encoded transcription activa-
tors, e.g. the HBV X protein (28,29), should facilitate tran-
scription regulation with consequent attenuation of oﬀ
target eﬀects.
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Figure 7. Assessment of eﬀects of pri-miR-31 shuttles on endogenous
miR-16 function using dual luciferase reporter and sponge vectors. (A)
Schematic illustration to show dual luciferase psiCHECK-derived
vector with seven copies of miR-16 target inserted downstream of the
Renilla luciferase ORF. Fireﬂy luciferase constitutively expressed from
the same plasmid was used to normalize data. (B) Schematic illustration
of expression cassette that generates a transcript containing seven
copies of an imperfectly matched miR-16 target. The transcript con-
tains 50 U6+27 and 30 stem sequences, which are thought to improve
stability of U6 Pol III transcripts. (C) Analysis of eﬀects of pri-miR-31
expression cassettes on endogenous miR-16 repression of target repor-
ter sequence using a dual luciferase assay. Co-transfection of reporter
plasmid, containing seven copies of miR-16 target inserted downstream
of the Renilla luciferase ORF, was carried out together with RNAi
expression cassettes, empty backbone plasmid (mock) or miR-16
sponge plasmid. Ratio of Renilla to Fireﬂy luciferase activity was mea-
sured to assess derepression of endogenous miR-16 by coexpressed miR
shuttles.
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